{"id":6539,"date":"2021-02-09T12:12:03","date_gmt":"2021-02-09T11:12:03","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/02\/FR-Seventure-round-up_IO_FINAL-002.pdf"},"modified":"2021-02-09T12:12:03","modified_gmt":"2021-02-09T11:12:03","slug":"fr-seventure-round-up_io_final-002-2","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/health-for-life-capital-ii-fund-managed-by-seventure-partners-makes-two-new-immuno-oncology-i-o-investments\/fr-seventure-round-up_io_final-002-2\/","title":{"rendered":"FR-Seventure round-up_IO_FINAL (002)"},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-6539","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"\n